سوق العوازل الدوائية في أوروبا، حسب النوع (العوازل المعقمة، عوازل الاحتواء، العوازل البيولوجية، عوازل أخذ العينات والوزن، عوازل تصنيع المكونات الصيدلانية النشطة (API)، عوازل الأدوية المشعة، عوازل الإنتاج، أخرى)، نوع النظام (نظام مغلق، نظام مفتوح)، الضغط (ضغط إيجابي، ضغط سلبي)، التكوين (واقف على الأرض، معياري، متحرك، مضغوط، سطح طاولة، محمول ، أخرى)، التطبيق (اختبار التعقيم، التصنيع، أخذ العينات / الوزن / التوزيع، تصنيع الأجهزة الطبية )، المستخدم النهائي (المستشفيات، مختبرات التشخيص، المعاهد الأكاديمية والبحثية، شركات الأدوية والتكنولوجيا الحيوية، منظمات أبحاث العقود، أخرى)، قناة التوزيع (العطاء المباشر، مبيعات التجزئة، موزعو الطرف الثالث) اتجاهات الصناعة والتوقعات حتى عام 2029.
تحليل ورؤى حول سوق العازل الدوائي في أوروبا
تُستخدم العوازل الصيدلانية في صناعة الأدوية كنظام حاجز خالٍ من التلوث. الاختبارات الميكروبيولوجية، ومعالجة العلاج الخلوي، والتصنيع الصيدلاني المتقدم (ATMP)، ووزن وتعبئة وتوزيع المنتجات القابلة للحقن المعقمة ليست سوى عدد قليل من تطبيقات العوازل الصيدلانية. يتم دعم استخدام العوازل الصيدلانية من خلال النمو المستمر لسوق الأدوية في البلدان النامية والمتقدمة وزيادة نفقات البحث والتطوير لإنتاج علاجات مبتكرة. أدت العوازل الطبية المتقدمة ومتطلبات صناعة الأدوية إلى قيام الشركات المصنعة الكبرى بتنمية صناعة العوازل الطبية. يعد الاستخدام المتزايد للمركبات الخطرة، والتكلفة المتزايدة لعدم الامتثال، وزيادة مختبرات الأبحاث من المحركات المهمة التي تدفع سوق العوازل الصيدلانية خلال فترة التنبؤ.
ومع ذلك، فإن معظم الخبراء لا يتفقون على أن الكيانات التنظيمية لم تعد تقف عائقا أمام تحقيق إنجازات مثل تطوير العوازل الدوائية.
تحلل شركة Data Bridge Market Research أن سوق العازل الدوائي في أوروبا من المتوقع أن تصل قيمته إلى 1,857.44 مليون دولار أمريكي بحلول عام 2029، بمعدل نمو سنوي مركب يبلغ 13.8% خلال الفترة المتوقعة. يشكل النوع أكبر شريحة من النوع في السوق بسبب الطلب السريع على العازل الدوائي في المنطقة. يغطي تقرير السوق هذا أيضًا تحليل الأسعار وتحليل براءات الاختراع والتقدم التكنولوجي بعمق.
|
تقرير القياس |
تفاصيل |
|
فترة التنبؤ |
2022 إلى 2029 |
|
سنة الأساس |
2021 |
|
سنوات تاريخية |
2020 (قابلة للتخصيص حتى 2019 - 2014) |
|
وحدات كمية |
الإيرادات بالملايين من الدولارات الأمريكية، الأحجام بالوحدات، التسعير بالدولار الأمريكي |
|
القطاعات المغطاة |
حسب النوع (العوازل المعقمة، عوازل الاحتواء، العوازل البيولوجية، عوازل أخذ العينات والوزن، عوازل تصنيع المكونات الصيدلانية النشطة (API)، عوازل الأدوية المشعة، عوازل الإنتاج، أخرى)، نوع النظام (نظام مغلق، نظام مفتوح)، الضغط (ضغط إيجابي، ضغط سلبي)، التكوين (مثبت على الأرض، معياري، متحرك، مضغوط، سطح طاولة، محمول، أخرى)، التطبيق (اختبار التعقيم، التصنيع، أخذ العينات / الوزن / التوزيع، تصنيع الأجهزة الطبية)، المستخدم النهائي (المستشفيات، مختبرات التشخيص، المعاهد الأكاديمية والبحثية، شركات الأدوية والتكنولوجيا الحيوية، منظمات أبحاث العقود، أخرى)، قناة التوزيع (العطاءات المباشرة، مبيعات التجزئة، موزعو الطرف الثالث). |
|
الدول المغطاة |
ألمانيا، فرنسا، المملكة المتحدة، إيطاليا، إسبانيا، روسيا، تركيا، بلجيكا، هولندا، سويسرا وبقية أوروبا، |
|
الجهات الفاعلة في السوق المشمولة |
Getinge، SKAN AG، Hosokawa micron ltd، Gelman Singapore، Azbil Corporation، Germfree Laboratories, Inc.، M. Braun Inertgas-Systeme Gmbh، Nuaire، Iteco SRL، Comecer SPA، Hecht Technologie Gmbh، Steriline SRL، Envair Limited، Tema Sinergie SPA، Schematic Engineering Industries، Chiyoda Corporation، Chamunda Pharma Machinery Pvt. Ltd، Bioquell (Ecolab Solution)، Jacomex، Fedegari Autoclavi SpA، LAF Technologies، ISO Tech Design، Cytiva، Esco Pharma وغيرها. |
تعريف سوق العازل الدوائي في أوروبا
إن مفهوم العزل يحمي العملية من المشغل أو المشغل من العملية، مع حماية البيئة. إن مفتاح الاحتواء هو التعرض الأدنى. من خلال التحكم في نطاق التعرض أسفل مستوى الخطر المحدد للمركب، يتم حماية المشغل والبيئة بشكل صحيح. وبالتالي، يتم حماية المنتج وبالتالي يتم معالجة قضية تنظيمية رئيسية. إن العازل الصيدلاني عبارة عن حاوية بكتيرية محكمة الغلق تستخدم في محيط المستحضرات الصيدلانية للتعبئة المعقمة والعملية السامة. وهو مصنوع من عازل رئيسي معقم تمامًا حيث يتم التعامل مع المنتجات أو تخزينها أو تعبئتها باستخدام قفازات عالية تصل إلى الكتف توضع على أحد الجدران. يتيح العازل الصيدلاني التحكم في العمليات الصيدلانية واحتوائها. الظروف المطلوبة لعمل العازل الصيدلاني هي بيئة معقمة وخالية من الكائنات الحية الدقيقة القابلة للحياة. يضمن العازل الصيدلاني وضع منطقة الإنتاج والبيئة المعقمة في أماكن منفصلة. إن العازل الصيدلاني فعال من حيث التكلفة والكفاءة، مقارنة بغرف التنظيف لصناعة المستحضرات الصيدلانية في بيئة معقمة. إنه يخلق جوًا خاضعًا للرقابة أثناء عملية إنتاج الميكروبات والأدوية من خلال التكيف مع معايير شهادة المعايير المختلفة المطلوبة للعوازل وحواجز الوصول المقيد. إنه يضمن حماية المنتج والعاملين والبيئة في نفس الوقت.
تتنوع التطبيقات الوفيرة للعوازل الصيدلانية لأغراض الإنتاج والتحكم. يتم استخدامها أثناء مناولة أو نقل أو تعبئة الأدوية الصيدلانية الصلبة وشبه الصلبة أو المسحوقة، ومناولة وإيداع المحاليل والحقن. يتم تطبيق العوازل الصيدلانية في اختبار التعقيم، والمعالجة المعقمة للأنسجة أو أنظمة الإنتاج البيولوجية أو العينات المسببة للأمراض، وما إلى ذلك. يمكن استخدامها لإنتاج الأدوية والمنتجات الصيدلانية والتحكم فيها. من المتوقع أن يؤدي الطلب المتزايد على العوازل عبر صناعة الأدوية والتكنولوجيا الحيوية، إلى جانب انخفاض تكلفة التشغيل، وارتفاع صيانة الحالة المعقمة في إنتاج المنتجات الصيدلانية والطلب المتزايد على صناعة الأدوية الحيوية إلى دفع نمو السوق في فترة التنبؤ.
كما أن المبادرات الاستراتيجية التي يتخذها اللاعبون في السوق، والتقدم التكنولوجي في مجال العوازل الدوائية، وضمان التعقيم العالي، وزيادة الاستثمار في البنية التحتية للرعاية الصحية، كلها عوامل تزيد من الطلب على سوق العوازل الدوائية.
ديناميكيات سوق العازل الدوائي في أوروبا
يتناول هذا القسم فهم محركات السوق والمزايا والفرص والقيود والتحديات. وسيتم مناقشة كل هذا بالتفصيل أدناه:
السائقين
الطلب المتزايد على العوازل الصيدلانية في جميع أنحاء صناعة الأدوية المزدهرة
العازل الدوائي هو جهاز فصل يفصل الإجراء أو النشاط الدوائي عن المشغل والبيئة المجاورة. يتم استخدامه لأغراض مختلفة مثل:
- توفير بيئة معقمة مصنفة لنشاط أو إجراء وحمايتها من التلوث الميكروبي وغير الميكروبي الناجم عن المشغل والبيئة المجاورة والتي يشار إليها بحماية المنتج.
- منتج وقائي ضد التلوث الناتج عن منتج أو إجراء آخر، علاوة على ذلك في نفس الوقت أو أثناء العمليات السابقة. ويشار إلى ذلك بالحماية ضد التلوث الناتج عن الطريقة أو التلوث المتبادل.
تزايد مشاكل التلوث في وحدة التصنيع التي يأتي فيها العازل مما يخلق طلبًا على العازل الدوائي الذي يساعد في التلوث وإزالة التلوث.
- انخفاض تكلفة تشغيل العوازل الصيدلانية
إن العبوات المغلقة وفقًا لمعايير معينة من إحكام الغلق والتي تتكون من بيئة خاضعة للرقابة المؤهلة، مع تعديل الظروف المحيطة، يمتد تطبيق العازل من البحث والتطوير من خلال إنتاج الأدوية إلى الاستخدام المختبري، وخاصة لمراقبة الجودة الميكروبيولوجية. في حين أن الإنتاج المعقم للأدوية يتمتع بمعايير عالية للغاية من النظافة، وبيئات خالية من الجسيمات والجراثيم تقريبًا للإنتاج المعقم.
بسبب النمو في صناعة الأدوية وتوسيع نطاق المنتجات، يحتاج المزيد والمزيد من المصنعين والموردين إلى التفكير في الاستثمارات في أحدث التقنيات المضافة لتكنولوجيا الغرف النظيفة.
Aseptic processing of the pharmaceutical drugs is the major factor need to be included in good manufacturing practices meeting the government regulations. The high cost of the maintenance of the aseptic condition by clean room technology which is around 62% higher than the pharmaceutical isolators, shifting the manufacturers to acquire isolator’s technology and constraining the overall manufacturing cost of the pharmaceutical products.
Restraint
Stringent governmental regulations
Active Pharmaceutical Ingredients (API) and intermediates for pharmaceutical use (for instance biological, radiopharmaceutical, and pharmaceutical) and those used to production drugs for clinical trials are regulated under the Divisions 1A and 2, Part C of the Food and Drug Regulations.
- Division 1A, Part C of the Food and Drug Regulations describes activities for which Good Manufacturing Practices (GMP) compliance is required and must be demonstrated prior to the issuance of an API establishment license (EL).
- Division 2, Part C of the Food and Drug Regulations defines the requirements for the GMP of APIs and API intermediates, which are interpreted in the present guidance document.
Due to this strict regulation by the government that has to be followed for the production by the Good Manufacturing Practices (GMP) Guidelines for Active Pharmaceutical Ingredients (API) - (GUI-0104) which constraining the market growth rate.
Opportunity
- Strategic initiatives by market players
The rise in the pharmaceutical isolators market increases the need for strategic business ideas. It includes a partnership, business expansion, and other development. The rising demand for pharmaceuticals is significantly increasing the demand for excipient and to cope with this demand companies are building new manufacturing sites among other strategic initiatives.
These strategic initiatives such as product launches, agreement and business expansion by the major market player will boost the pharmaceutical isolator market growth and is expected to act as an opportunity for the Europe medical display market.
Challenge
Lack of skilled expertise
The shortage of skilled expertise would challenge the pace of recovery and growth in one place. Often, the people who are unemployed in one place have skills that are in short supply elsewhere. Moreover, rapid technological advancement in this field also leads to lack of expertise.
Lack of skilled professionals while handling the pharmaceutical isolators poses a major challenge while selecting and developing the pharmaceutical isolators. The data by the Phys.org 2003 mentions the medical display industries are facing a shortage of workers due to increase demand of pharmaceutical isolators in Asia-Pacific region and severe scarcity of micro chips used in LED and LCD display, which increases the price lead times of LCD production.
As skill demands are too high, it has manifested as a challenge to retain and manage skill-specified professionals. Moreover, technological advancement is another aspect that leads to the increased demand for skilled professionals. Neurologists report significant unmet supportive care needs and barriers in their centers with only a small minority rating themselves as competently providing supportive care. There is an urgent need for education of neurologists and professionals for treatment of dementia and procuring available supportive care resources. Lack of trained and experienced professionals and persistent skill gaps limit the employability prospects and access to quality jobs. It is therefore apparent that availability of professionals equipped with adequate skills is expected to challenge the market growth.
Post-COVID-19 Impact on Europe Pharmaceutical Isolator Market
The COVID-19 pandemic has become the world's most serious threat. It wreaked havoc in many stores and businesses around the world. The pandemic, on the other hand, has provided many opportunities for pharmaceutical and biopharmaceutical companies to expand their research and development activities to develop new vaccines against the new coronavirus. Companies are conducting clinical trials to try to stop the spread of the COVID-19 virus. Pharmaceutical insulator suppliers to biopharmaceutical organizations have more opportunities as the number of clinical trials increases.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the pharmaceutical medical display market.
Recent Developments
- In June 2022, the company announced a partnership with Medical Supply Company (MSC) to market and service Jacomex equipment to the pharmaceutical and pharmaceutical industries in Ireland. MSC has many years of recognized expertise in the market with field teams closest to customers and company’s commercial team currently working abroad had the pleasure of welcoming Cian Murphy and finalizing the agreement between Jacomex and MSC. The beginning of a long and fruitful collaboration. This has helped the company to expand their business.
- In January 2022, Clario partnered with XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, to deliver PET imaging clinical trials for testing novel therapeutics in China. The partnership offers to share the joint resources and neuroscience experts of Clario and XingImaging to expedite the startup of clinical trials and drug discovery in China.
Europe Pharmaceutical isolator market Scope
Europe pharmaceutical isolator market is segmented into type, pressure, application, configuration, system type, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY TYPE
- ASEPTIC ISOLATORS
- CONTAINMENT ISOLATORS
- BIO ISOLATORS
- SAMPLING AND WEIGHING ISOLATORS
- ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING ISOLATORS
- RADIOPHARMACEUTICAL ISOLATORS
- PRODUCTION ISOLATORS
- OTHERS
On the basis of type, the Europe pharmaceutical isolator market is segmented into aseptic isolators, containment isolators, bio isolators, sampling and weighing isolators, active pharmaceutical ingredient (API) manufacturing isolators, radiopharmaceutical isolators, production isolators, others.
EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE
- CLOSED SYSTEM
- OPEN SYSTEM
On the basis of system type, the Europe pharmaceutical isolator market is segmented into closed system, open system.
EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE
- POSITIVE PRESSURE
- NEGATIVE PRESSURE
On the basis of pressure, the Europe pharmaceutical isolator market is segmented into positive pressure and negative pressure.
EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION
- FLOOR STANDING
- MODULAR
- MOBILE
- COMPACT
- TABLE TOP
- PORTABLE
- OTHERS
On the basis of configuration, the Europe pharmaceutical isolator market is segmented into floor standing, modular, mobile, compact, table top, portable, others.
EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION
- STERILITY TESTING
- MANUFACTURING
- SAMPLING/ WEIGHING/ DISTRIBUTION
- MEDICAL DEVICE MANUFACTURING
- OTHERS
On the basis of application, the Europe pharmaceutical isolator market is segmented into sterility testing, manufacturing, sampling/ weighing/ distribution, medical device manufacturing, others.
EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY END USER
- HOSPITALS
- DIAGNOSTIC LABORATORIES
- ACADEMIC AND RESEARCH INSTITUTES
- PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
- CONTRACT RESEARCH ORGANIZATIONS
- OTHERS
On the basis of end user, the Europe pharmaceutical isolator market is segmented into hospitals, diagnostic laboratories, academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations, others.
EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL
- DIRECT TENDER
- RETAIL SALES
- THIRD PARTY DISTRIBUTORS
On the basis of distribution channel, the Europe pharmaceutical isolator market is segmented into direct tender, retail sales, third party distributors.
Europe Pharmaceutical Isolator Market Regional Analysis/Insights
The Europe pharmaceutical isolator market is analyzed and market size information is provided type, pressure, application, configuration, system type, end user and distribution channel.
The countries covered in this market report Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland and the rest of Europe.
In 2022, Germany is dominating due to rapidly growing pharmaceutical market coupled with rise in pharmaceutical equipments production and increasing demand from emerging markets and expansion of healthcare industries.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Pharmaceutical Isolator Market Share Analysis
Europe pharmaceutical isolator market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the Europe pharmaceutical isolator market.
Some of the major players operating in the Europe pharmaceutical isolator market are Getinge, SKAN AG, Hosokawa micron ltd, Gelman Singapore, Azbil Corporation, Germfree Laboratories, Inc., M. Braun Inertgas-Systeme Gmbh, Nuaire, Iteco S.R.L., Comecer S.P.A., Hecht Technologie Gmbh, Steriline S.R.L., Envair Limited, Tema Sinergie S.P.A, Schematic Engineering Industries, Chiyoda Corporation, Chamunda Pharma Machinery Pvt. Ltd, Bioquell (Ecolab Solution), Jacomex, Fedegari Autoclavi S.p.A., LAF Technologies, ISO Tech Design, Cytiva, Esco Pharma.
Research Methodology: Europe Pharmaceutical Isolator Market
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. بالإضافة إلى ذلك، يعد تحليل حصة السوق وتحليل الاتجاهات الرئيسية من عوامل النجاح الرئيسية في تقرير السوق. منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي مثلث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأساسي (خبير الصناعة). وبصرف النظر عن هذا، تتضمن نماذج البيانات شبكة وضع البائعين، وتحليل الخط الزمني للسوق، ونظرة عامة على السوق والدليل، وشبكة وضع الشركة، وتحليل حصة الشركة في السوق، ومعايير القياس، وأوروبا مقابل المنطقة، وتحليل حصة البائعين. يرجى طلب مكالمة محلل في حالة وجود استفسار آخر.
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE PHARMACEUTICAL ISOLATOR MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 INDUSTRIAL INSIGHTS:
5 EUROPE PHARMACEUTICAL ISOLATORS MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING DEMAND FOR THE PHARMACEUTICAL ISOLATORS ACROSS BOOMING PHARMACEUTICAL
6.1.2 LOW OPERATIONAL COST OF PHARMACEUTICAL ISOLATORS
6.1.3 HIGH MAINTENANCE OF ASEPTIC CONDITIONS IN THE PRODUCTION OF PHARMACEUTICAL PRODUCTS
6.1.4 LOW OPERATING COST OF PHARMACEUTICAL ISOLATORS & GROWING DEMAND IN THE BIOPHARMACEUTICAL INDUSTRY
6.2 RESTRAINTS
6.2.1 STRINGENT GOVERNMENTAL REGULATIONS
6.2.2 HIGH COST OF INSTALLATION & LIMITED ADOPTION OF RABS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.2 TECHNOLOGICAL ADVANCEMENTS IN PHARMACEUTICAL ISOLATORS
6.3.3 HIGH STERILITY ASSURANCE
6.4 CHALLENGES
6.4.1 LACK OF SKILLED EXPERTISE
6.4.2 ENGINEERING CHALLENGES FACED WHILE DESIGNING THE PHARMACEUTICAL ISOLATORS
7 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY TYPE
7.1 OVERVIEW
7.2 ASEPTIC ISOLATOR
7.3 ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING ISOLATORS
7.4 CONTAINMENT ISOLATORS
7.5 BIO ISOLATORS
7.6 SAMPLING AND WEIGHING ISOLATORS
7.7 RADIOPHARMACEUTICAL ISOLATORS
7.8 PRODUCTION ISOLATORS
7.9 OTHERS
8 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE
8.1 OVERVIEW
8.2 OPEN SYSTEM
8.3 CLOSED SYSTEM
9 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE
9.1 OVERVIEW
9.2 POSITIVE PRESSURE
9.3 NEGATIVE PRESSURE
10 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION
10.1 OVERVIEW
10.2 FLOOR STANDING
10.3 MODULAR
10.4 MOBILE
10.5 COMPACT
10.6 TABLE TOP
10.7 PORTABLE
10.8 OTHERS
11 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 STERILITY TESTING
11.3 MANUFACTURING
11.4 SAMPLING/WEIGHING/DISTRIBUTION
11.5 MEDICAL DEVICE MANUFACTURING
12 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 THIRD PARTY DISTRIBUTORS
13 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY END USER
13.1 OVERVIEW
13.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
13.2.1 STERILE FILTERING
13.2.2 AMPULE FILLING
13.2.3 SYRINGE FILLING
13.2.4 SAMPLING
13.2.5 SAMPLE TESTING
13.2.6 STERILITY TESTING
13.2.7 PACKAGING
13.2.8 OTHERS
13.3 CONTRACT RESEARCH ORGANIZATION
13.3.1 STERILE FILTERING
13.3.2 AMPULE FILLING
13.3.3 SYRINGE FILLING
13.3.4 SAMPLING
13.3.5 SAMPLE TESTING
13.3.6 STERILITY TESTING
13.3.7 PACKAGING
13.3.8 OTHERS
13.4 ACADEMIC AND RESEARCH INSTITUTES
13.4.1 STERILE FILTERING
13.4.2 AMPULE FILLING
13.4.3 SYRINGE FILLING
13.4.4 SAMPLING
13.4.5 SAMPLE TESTING
13.4.6 STERILITY TESTING
13.4.7 PACKAGING
13.4.8 OTHERS
13.5 HOSPITALS
13.5.1 STERILE FILTERING
13.5.2 AMPULE FILLING
13.5.3 SYRINGE FILLING
13.5.4 SAMPLING
13.5.5 SAMPLE TESTING
13.5.6 STERILITY TESTING
13.5.7 PACKAGING
13.5.8 OTHERS
13.6 DIAGNOSTIC LABORATORIES
13.6.1 STERILE FILTERING
13.6.2 AMPULE FILLING
13.6.3 SYRINGE FILLING
13.6.4 SAMPLING
13.6.5 SAMPLE TESTING
13.6.6 STERILITY TESTING
13.6.7 PACKAGING
13.6.8 OTHERS
13.7 OTHERS
14 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY REGION
14.1 EUROPE
14.1.1 GERMANY
14.1.2 FRANCE
14.1.3 U.K.
14.1.4 ITALY
14.1.5 RUSSIA
14.1.6 SPAIN
14.1.7 TURKEY
14.1.8 NETHERLANDS
14.1.9 SWITZERLAND
14.1.10 BELGIUM
14.1.11 REST OF EUROPE
15 EUROPE PHARMACEUTICAL ISOLATORS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 GETINGE AB
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 CYTIVA (A SUBSIDIARY OF DANAHER CORPORATION)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 AZBIL CORPORATION
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 CHIYODA CORPORATION
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 HOSOKAWA MICRON LTD
17.5.1 COMPANY SNAPSHOT
17.5.2 COMPANY SHARE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 BIOQUELL, AN ECOLAB SOLUTION (A SUBSIDIARY OF ECOLAB)
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 CHAMUNDA PHARMA MACHNIERY
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 COMECER S.P.A. (A SUBSIDIARY OF ATS AUTOMATION TOOLS) (2021)
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 ENVAIR TECHNOLOGY
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 ESCO MICRO PTE. LTD
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 FEDEGARI AUTOCLAVI S.P.A
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 GERMFREE LABORATORIES, INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 GELMAN SINGAPORE
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 HECT TECHNOLOGIE GMBH (2021)
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 ISO TECH DESIGN
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENTS
17.16 ITECO SRL
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 JACOMEX
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 LAF TECHNOLOGIES
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENTS
17.19 MBRAUN.(2021)
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 NUAIRE (A SUBSIDIARY OF GENUIT GROUP PLC)
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 STERILINE (2021)
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENTS
17.22 SCHEMATIC ENGINEERING INDUSTRY
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENTS
17.23 SKAN AG
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 TEMA SINERGIE S.P.A
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 OPERATING COSTS FOR ASEPTIC PRODUCTION UNDER RABS OR ISOLATOR
TABLE 2 APPLICATION OF GUI-0104 TO API MANUFACTURING
TABLE 3 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 EUROPE ASEPTIC ISOLATOR IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE CONTAINMENT ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE BIO ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE SAMPLING AND WEIGHING ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE RADIOPHARMACEUTICAL ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE PRODUCTION ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE OTHERS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 13 EUROPE OPEN SYSTEM IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE CLOSED SYSTEM IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE POSITIVE PRESSURE IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE NEGATIVE PRESSURE IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE FLOOR STANDING IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE MODULAR IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE MOBILE IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE COMPACT IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE TABLE TOP IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE PORTABLE IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE OTHERS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE STERILITY TESTING IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE MANUFACTURING IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE SAMPLING/WEIGHING/DISTRIBUTION IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE MEDICAL DEVICE MANUFACTURING IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 32 EUROPE DIRECT TENDER IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE RETAIL SALES INPHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE THIRD PARTY DISTRIBUTORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 36 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 38 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 40 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 42 EUROPE HOSPITALS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE HOSPITALS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 EUROPE DIAGNOSTIC LABARATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 EUROPE DIAGNOSTICS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 46 EUROPE OTHERS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 47 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 48 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 50 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 51 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 52 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 53 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 55 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 56 EUROPE ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 57 EUROPE HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 58 EUROPE DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 59 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 60 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 62 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 63 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 64 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 65 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 66 GERMANY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 67 GERMANY CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 GERMANY ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 69 GERMANY HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 GERMANY DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 71 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 74 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 75 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 76 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 77 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 78 FRANCE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 79 FRANCE CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 80 FRANCE ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 81 FRANCE HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 82 FRANCE DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 83 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 86 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 87 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 88 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 89 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 90 U.K. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 91 U.K. CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 92 U.K. ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 U.K. HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 U.K. DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 95 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 96 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 98 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 99 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 100 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 101 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 102 ITALY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 103 ITALY CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 104 ITALY ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 105 ITALY HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 106 ITALY DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 107 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 108 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 110 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 111 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 112 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 113 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 114 RUSSIA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 115 RUSSIA CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 RUSSIA ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 117 RUSSIA HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 118 RUSSIA DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 119 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 120 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 122 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 123 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 124 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 125 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 126 SPAIN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 127 SPAIN CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 128 SPAIN ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 129 SPAIN HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 130 SPAIN DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 131 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 132 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 134 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 135 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 136 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 137 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 138 TURKEY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 139 TURKEY CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 TURKEY ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 141 TURKEY HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 142 TURKEY DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 143 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 144 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 146 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 147 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 148 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 149 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 150 NETHERLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 151 NETHERLAND CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 152 NETHERLAND ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 153 NETHERLAND HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 154 NETHERLAND DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 155 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 156 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 157 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 158 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 159 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 160 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 161 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 162 SWITZERLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 163 SWITZERLAND CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 164 SWITZERLAND ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 165 SWITZERLAND HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 166 SWITZERLAND DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 167 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 168 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 169 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 170 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 171 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 172 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 173 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 174 BELGIUM PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 175 BELGIUM CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 176 BELGIUM ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 177 BELGIUM HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 178 BELGIUM DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 179 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 180 REST OF EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 EUROPE PHARMACEUTICAL ISOLATOR MARKET: SEGMENTATION
FIGURE 2 EUROPE PHARMACEUTICAL ISOLATOR MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE PHARMACEUTICAL ISOLATOR MARKET: DROC ANALYSIS
FIGURE 4 EUROPE PHARMACEUTICAL ISOLATOR MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE PHARMACEUTICAL ISOLATOR MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE PHARMACEUTICAL ISOLATOR MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE PHARMACEUTICAL ISOLATOR MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE PHARMACEUTICAL ISOLATOR MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE PHARMACEUTICAL ISOLATOR MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE PHARMACEUTICAL ISOLATOR MARKET: SEGMENTATION
FIGURE 11 INCREASING USE OF PHARMACEUTICAL ISOLATORS IS EXPECTED TO DRIVE THE EUROPE PHARMACEUTICAL ISOLATOR MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 ASEPTIC ISOLATORS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PHARMACEUTICAL ISOLATOR MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE PHARMACEUTICAL ISOLATOR MARKET
FIGURE 14 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY TYPE, 2021
FIGURE 15 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 16 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 17 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY SYSTEM TYPE, 2021
FIGURE 19 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY SYSTEM TYPE, 2022-2029 (USD MILLION)
FIGURE 20 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY SYSTEM TYPE, CAGR (2022-2029)
FIGURE 21 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY SYSTEM TYPE, LIFELINE CURVE
FIGURE 22 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY PRESSURE, 2021
FIGURE 23 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY PRESSURE, 2022-2029 (USD MILLION)
FIGURE 24 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY PRESSURE, CAGR (2022-2029)
FIGURE 25 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY PRESSURE, LIFELINE CURVE
FIGURE 26 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY CONFIGURATION, 2021
FIGURE 27 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY CONFIGURATION, 2022-2029 (USD MILLION)
FIGURE 28 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY CONFIGURATION, CAGR (2022-2029)
FIGURE 29 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY CONFIGURATION, LIFELINE CURVE
FIGURE 30 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY APPLICATION, 2021
FIGURE 31 EUROPEPHARMACEUTICAL ISOLATOR MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 32 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 33 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 34 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 35 EUROPEPHARMACEUTICAL ISOLATOR MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 36 EUROPEPHARMACEUTICAL ISOLATOR MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 37 EUROPEPHARMACEUTICAL ISOLATOR MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 EUROPE PHARMACEUTICAL ISOLATOR MARKET : BY END USER, 2021
FIGURE 39 EUROPE PHARMACEUTICAL ISOLATOR MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 40 EUROPE PHARMACEUTICAL ISOLATOR MARKET : BY END USER, CAGR (2022-2029)
FIGURE 41 EUROPE PHARMACEUTICAL ISOLATOR MARKET : BY END USER, LIFELINE CURVE
FIGURE 42 EUROPE PHARMACEUTICAL ISOLATOR MARKET: SNAPSHOT (2021)
FIGURE 43 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY COUNTRY (2021)
FIGURE 44 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY COUNTRY (2022 & 2029)
FIGURE 45 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY COUNTRY (2021 & 2029)
FIGURE 46 EUROPE PHARMACEUTICAL ISOLATOR MARKET: TYPE (2022-2029)
FIGURE 47 EUROPE PHARMACEUTICAL ISOLATORS MARKET: COMPANY SHARE 2021 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
